Clinical trials: Oncologic
Healthy Volunteer
Bioequivalence Study Evaluating the Pharmacokinetics of DMB-3111 and Trastuzumab in Healthy Japanese Male Adults
This study is a randomized Trastuzumab-controlled double-blind parallel-group study.
- Trial name
- NCT02100917
- Testing
- DMB-3111, trastuzumab
- Where
- Japan
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Meiji Seika Pharma Co., Ltd.
Oncology, Medical Devices
Capillary-Venous Paired Data Collection
Capillary-venous paired data collection.
- Conditions
- Oncology, Medical Devices, Healthy Subjects
- Trial name
- CaVeP-DC (NCT05926362)
- Where
- 2 sites in United Kingdom
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Entia Ltd
Medical Oncology, Cancer
Ezra Faster Scan Study
The Ezra Faster Scan study uses non-invasive magnetic resonance imaging (MRI) technology that can "visually" detect early and late-stage cancer, and other pathologies.
- Conditions
- Medical Oncology, Cancer, Healthy
- Trial name
- FasterScan (NCT05385718)
- Testing
- Magnetic Resonance Imaging
- Where
- 5 sites in United States
- Volunteers
- 694 people, healthy volunteers welcome
- Sponsor
- Ezra AI, Inc.
Prostate Cancer, Urine
Investigation of Urinary Biomarkers for the Detection of Prostate Cancer
The aim of this study is to investigate and possibly validate urinary biomarkers for prostate cancer. During this study the focus will be on aberrations of selected genes as prognostic or predictive value has been shown for these…
- Conditions
- Prostate Cancer, Urine, Liquid Biopsy
- Trial name
- URODETECT-WP2 (NCT05454371)
- Testing
- Colli-Pee UAS devices
- Where
- Belgium
- Volunteers
- healthy volunteers welcome
- Sponsor
- Novosanis NV
Acute Myelogenous Leukemia, Ovarian Cancer
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
To evaluate the safety, tolerability, and anti-tumor activity of galinpepimut-S in combination with pembrolizumab in patients with selected advanced cancers.
- Conditions
- Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer
- Trial name
- NCT03761914
- Testing
- galinpepimut-S, pembrolizumab, Montanide
- Where
- 12 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Sellas Life Sciences Group
Ovarian Cancer, Breast Cancer
Comprehensive Outcomes for After Cancer Health
This study intends to explore feasibility, acceptability, and outcomes related to the use of a digital health coaching intervention for individuals who have completed primary therapy for cancer.
- Conditions
- Ovarian Cancer, Breast Cancer, Lung Cancer, Gastric Cancer
- Trial name
- COACH (NCT05349227)
- Testing
- Digital Health Coaching Program, Fitbit
- Where
- 7 sites in United States
- Volunteers
- 625 people, healthy volunteers welcome
- Sponsor
- Pack Health
Vascular Access Complication
Effectiveness of the Rapid Intravascular Start (RIVS) System Versus Conventional Catheter
The study will test a hypothesis that the RIVS system will have a higher rate of successful first PIV placement compared to conventional catheter without a significant increase in complications and time of procedure.
- Trial name
- NCT00914069
- Testing
- RIVS vascular access, Conventional vascular access
- Where
- 3 sites in United States
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- C. R. Bard
Healthy
A Pharmacokinetic Study Comparing PF-06439535 And Bevacizumab In Healthy Male Volunteers (REFLECTIONS B739-01)
This study is to prove that the handling (also referred to as pharmacokinetics) of the following drugs PF-06439535, Avastin® (bevacizumab) that is licensed for use in the United States (bevacizumab-US) and Avastin® (bevacizumab)…
- Trial name
- NCT02031991
- Testing
- PF-06439535, Avastin
- Where
- United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Pfizer
H1N1 Influenza Virus, Invasive Solid Tumors
Clinical Trial to Compare the Immunogenicity, Safety, and Tolerability of an Adjuvanted A(H1N1) Influenza Vaccine Versus Non-Adjuvanted A(H1N1) Influenza Vaccines in Patients With Invasive Solid Tumors
This is a phase III, randomized, controlled, open label study with two vaccine regimens. The study will assess the relative safety and immunogenicity of vaccine regimens comparing adjuvanted versus non-adjuvanted formulations of…
- Trial name
- NCT01031719
- Testing
- adjuvanted A(H1N1) influenza vaccine, non-adjuvanted A(H1N1) influenza vaccine
- Where
- 3 sites in Brazil
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Chiltern Pesquisa Clinica Ltda
Cancer
Polaris Oncology Survivor Transition (POST) System
The POST's public health impact is likely to be substantial because it will improve cancer survivorship planning, which is currently an important deficiency in cancer care recognized by the Institute of Medicine and the American…
- Trial name
- POST (NCT02637349)
- Testing
- POST Intervention, POST Treatment as Usual
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Polaris Health Directions
Oncology
Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function
The primary objective of this study is to evaluate the pharmacokinetics of entospletinib (ENTO) and/or its metabolites (if applicable) in participants with impaired hepatic function (stratified by smoking status, as appropriate)…
- Trial name
- NCT02521376
- Testing
- Entospletinib
- Where
- 6 sites in United States, Germany and 1 more
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Cancer
A Prospective Registry to Enable Collection of Standardized Routine Care Oncology Patient Data
This is an observational registry for patients at participating oncology centers. The data collection includes but is not limited to baseline variables, treatments given and outcome data. Patient surveys are also included.
- Trial name
- NCT06877884
- Where
- 7 sites in United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- N-Power Medicine
Oncology
A Phase I, Open-label Study to Assess Bioavailability of a Single Oral Dose of AZD9291 vs an IV Dose of [14C]AZD9291
The Sponsor is developing the study drug, AZD9291, for the potential treatment of nonsmall cell lung cancer. Lung cancer has been the most common cancer in the world for several decades and represents 12.8% of all new cancer…
- Trial name
- NCT02491944
- Testing
- AZD9291, [14C]AZD9291
- Where
- United Kingdom
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
Pharmacokinetic Equivalence and Safety Study of RPH-001 and Avastin®
The purpose of this study is to confirm pharmacokinetic equivalence and compare clinical safety profile of RPH-001 and Avastin®.
- Trial name
- NCT03659305
- Testing
- RPH-001, Avastin
- Where
- Russia
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- R-Pharm
Infectious Disease, Neoplasms
AnovaOS Network Powered Patient Registry
The objective of this study is the development, implementation and management of a registry of patient data that captures clinically meaningful, real-world, data on the diagnosis, nature, course of infection, treatment(s) and…
- Conditions
- Infectious Disease, Neoplasms, Diseases of the Blood and Blood-Forming Organs and Certain Disorders Involving the Immune Mechanism (D50-D89), Endocrine, Nutritional and Metabolic Diseases (E00-E89)
- Trial name
- NCT05013944
- Where
- United States
- Volunteers
- 100,000 people, healthy volunteers welcome
- Sponsor
- Anova Enterprises, Inc
Oncology
3-part Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EXS21546
A 3-part Study to Assess Safety, Tolerability, PK and PD of Single (Part 1) and Multiple (Part 2) Ascending Doses of EXS21546, and to Evaluate the Relative Bioavailability of a Solid Dose Formulation Compared to a Powder for Oral…
- Trial name
- NCT04727138
- Testing
- EXS21546 Powder for Oral Suspension, EXS21546 Granule in Capsule, Midazolam
- Where
- United Kingdom
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Exscientia AI Limited
Oncology, Hematologic Malignancy
AUD Biomarkers Study (Proteomic and Genomic Analysis of Biospecimens)
Study purpose: to explore the entire spectrum of proteomic and genomic changes (amongst others) involved in diseases and in healthy/control populations.
- Conditions
- Oncology, Hematologic Malignancy, Gastro-Intestinal Disorder, Autoimmune Diseases
- Trial name
- NCT05889806
- Testing
- Observational Study Only. NO Intervention.
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Audubon Bioscience
Breast Cancer, Urine
Investigation of Urinary Biomarkers for the Detection of Breast Cancer
The aim of this study is to investigate and possibly validate urinary biomarkers for breast cancer. During this study the focus will be on aberrations of selected genes as prognostic or predictive value has been shown for these…
- Conditions
- Breast Cancer, Urine, Liquid Biopsy
- Trial name
- URODETECT-WP3 (NCT05453591)
- Testing
- Colli-Pee UAS devices
- Where
- Belgium
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Novosanis NV
Healthy
A Pharmacokinetic Study Comparing PF-05280014 And Trastuzumab In Healthy Male Volunteers (REFLECTIONS B327-01)
In this study, healthy male volunteers will receive a single intravenous administration of either PF-05280014 or trastuzumab (United States) or trastuzumab (European Union).
- Trial name
- NCT01603264
- Testing
- PF-05280014, Herceptin
- Where
- United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Pfizer
Colon Cancer, Breast Cancer
A Digimed Oncology PharmacoTherapy Registry
DigiMeds™ are medications with FDA-approved ingestible sensors (IS), a wearable sensor patch (patch), and a mobile app, which records time-stamped medication type and dose alongside biometric activity.
- Conditions
- Colon Cancer, Breast Cancer, Rectal Cancer
- Trial name
- ADOPTR (NCT04088955)
- Testing
- DigiMeds
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Proteus Digital Health, Inc.